Inertia in Adaptation of Healthcare System to Biologics and Biosimilars

Biologics and biosimilars are underused. Different manufacturing, regulatory and social barriers, and clinical inertia prevent its adequate usage despite indications. Awareness of clinicians, patient education, reduction of costs, regulatory easing, and simplification of manufacturing processes will help in the earlier adaptation of biologics in the healthcare system. Further advancement of technologies will help to generate biologics and biosimilars of greater safety, better efficacy, lesser immunogenicity, and good interchangeability.